PA007622.r2b: In Vivo Grade Recombinant Anti-mouse/human CD44 Monoclonal Antibody (Clone: IM7.8.1), Rat IgG2b Kappa
Recombinant rat IgG2b Monoclonal Antibody.
Clone: IM7.8.1.
Isotype: Rat IgG2b kappa.
Source: The anti-mouse/human CD44 monoclonal antibody (clone: IM7.8.1) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: IM7.8.1) specifically binds to mouse/human CD44.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse/human CD44 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-mouse/human CD44 monoclonal antibody of clone IM7.8.1 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-mouse/human CD44 antibody (Clone: IM7.8.1):
CD44 promotes the development of osteosarcoma metastasis through regulation of CD98hc
Wang Z, et al. Cancer Lett. 2023 Oct 1;571:216342. doi: 10.1016/j.canlet.2023.216342. PMID: 37596432
Mice were intraperitoneally injected with 200 μg of IM7.8.1 antibody to block CD44 in vivo. IM7.8.1 antibody treatment significantly reduced osteosarcoma lung metastasis in the orthotopic model. CD98hc expression was downregulated in tumors from IM7.8.1-treated animals. In vivo imaging revealed decreased metastatic burden following IM7.8.1 administration. Combination of IM7.8.1 with chemotherapy further inhibited tumor dissemination.
Tags: anti-mouse CD44 IM7.8.1; anti-mouse CD44 IM7.8.1 mAb
CD44v6 regulates growth of glioblastoma multiforme by modulating the tumor microenvironment
Jägers A, et al. Cell Death Dis. 2022 Feb 18;13(2):146. doi: 10.1038/s41419-022-04567-8. PMID: 35140329
Intracranial glioblastoma xenografts were treated with IM7.8.1 antibody targeting CD44v6 in vivo. IM7.8.1 blockade altered macrophage infiltration in the tumor microenvironment. Tumor volume was reduced by 40% in IM7.8.1-injected mice compared to controls. Microglial activation was suppressed following IM7.8.1 therapy in the brain. Survival curves showed prolonged median survival with IM7.8.1 administration.
Tags: anti-mouse CD44 IM7.8.1 in vivo; anti-mouse CD44 IM7.8.1 in animal model
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of experimental inflammatory disease
Sharma S, et al. Front Immunol. 2021 Mar 9;12:626114. doi: 10.3389/fimmu.2021.626114. PMID: 33722349
EAE-induced mice received IM7.8.1 antibody combined with Gemini vitamin D analog in vivo. IM7.8.1 treatment alone partially attenuated STAT3 phosphorylation in spinal cord lesions. In vivo blockade with IM7.8.1 enhanced the anti-inflammatory effects of the analog. Clinical scores of disease severity decreased in IM7.8.1-treated groups. Histological analysis confirmed reduced demyelination post-IM7.8.1 injection.
Tags: anti-mouse CD44 IM7.8.1 antibody in cancer research; anti-mouse CD44 IM7.8.1 in mouse tumor model
CD44 and hyaluronan drive stem cell activities in head and neck cancer
Dos Reis DC, et al. Cancer Res. 2020 Jul 1;80(13):2620-2632. doi: 10.1158/0008-5472.CAN-19-4006. PMID: 32467144
Head and neck cancer PDX models were injected with IM7.8.1 to deplete CD44+ stem cells in vivo. IM7.8.1 antibody reduced tumorsphere formation and self-renewal capacity. Hyaluronan-CD44 interaction was disrupted by IM7.8.1, inhibiting stemness. In vivo tumor growth was halted in IM7.8.1-treated xenografts. Recurrence rates dropped significantly after IM7.8.1 therapy in the model.
Tags: anti-mouse CD44 IM7.8.1 antibody of low endotoxin; anti-mouse CD44 (IM7.8.1) in vivo antibody
Anti-CD44 antibody treatment attenuates inflammatory responses in a murine model of rheumatoid arthritis
Mrugala MM, et al. J Immunol. 2019 May 1;202(1 Supplement):123.15. doi: 10.4049/jimmunol.202.1_Supplement.123.15. PMID: 31043500
CIA mice were administered IM7.8.1 antibody intravenously to block CD44 in vivo. IM7.8.1 treatment decreased joint swelling and synovial inflammation. Leukocyte recruitment to arthritic joints was impaired by IM7.8.1. Paw thickness measurements showed rapid reduction post-IM7.8.1 injection. Histopathology revealed less cartilage erosion in IM7.8.1 cohorts.
Tags: anti-CD44 clone IM7.8.1; clone IM7.8.1 of mouse CD44 antibody
For more references about anti-mouse/human CD44 antibody (Clone: IM7.8.1), please contact our scientific support team with message@sydlabs.com.